Oncternal Therapeutics (NASDAQ:ONCT) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a report issued on Wednesday. The brokerage set a “hold” rating on the stock.

Other equities analysts have also issued research reports about the stock. Northland Securities reissued a “market perform” rating and issued a $2.00 price target on shares of Oncternal Therapeutics in a report on Thursday, September 12th. Northland Capmk lowered Oncternal Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, September 12th. Brookline Capital Management reissued a “hold” rating on shares of Oncternal Therapeutics in a research note on Thursday, September 12th. Finally, HC Wainwright cut their price objective on shares of Oncternal Therapeutics from $19.00 to $18.00 and set a “buy” rating for the company in a research note on Monday, August 12th. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $20.00.

Oncternal Therapeutics Stock Performance

Oncternal Therapeutics stock opened at $1.25 on Wednesday. Oncternal Therapeutics has a fifty-two week low of $1.23 and a fifty-two week high of $13.14. The stock has a market cap of $3.70 million, a P/E ratio of -0.10 and a beta of 1.39. The firm’s fifty day moving average price is $3.97 and its 200-day moving average price is $6.79.

Oncternal Therapeutics (NASDAQ:ONCT) last posted its earnings results on Thursday, August 8th. The company reported ($2.89) EPS for the quarter, topping the consensus estimate of ($3.03) by $0.14. Oncternal Therapeutics had a negative return on equity of 136.10% and a negative net margin of 1,948.70%. The business had revenue of $0.80 million during the quarter, compared to analysts’ expectations of $0.24 million. During the same period in the previous year, the business earned ($3.00) earnings per share. Sell-side analysts predict that Oncternal Therapeutics will post -11.43 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Oncternal Therapeutics stock. Pasadena Private Wealth LLC acquired a new stake in shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned about 0.84% of Oncternal Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 16.05% of the company’s stock.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.